非酒精性脂肪性肝病儿童血清人尾肢同源蛋白水平检测的临床意义
发布时间：2018-11-10 19:38
【摘要】：目的目前仍不了解非酒精性脂肪性肝病(NAFLD)患儿人尾肢同源蛋白(Pygo2)血清水平在疾病进展过程中作用,以及可否评估肝纤维化程度。文中旨在检测肥胖儿童外周血中的Pygo2水平,并分析其与传统肝纤维化血清学指标之间的关系,从而评估NAFLD患儿Pygo2检测的实际临床价值。方法选择2014年9月至2016年2月在安徽医科大学附属省立医院和南京医科大学第一附属医院就诊的住院和门诊肥胖患儿120例。参考NAFLD诊疗指南将120例肥胖患儿分为单纯性肥胖组(n=44例,肝B超无弥漫性脂肪肝的肥胖儿童)、单纯性非酒精性脂肪肝(NAFL)组(n=35例,肝B超提示有弥漫性脂肪肝但肝功能正常)、非酒精性脂肪肝炎(NASH)组(n=41例,肝B超提示有弥漫性脂肪肝且肝功能异常)。另选取18例健康志愿者为对照组。对照组及所有患者均收集外周血清,并分别采用酶联免疫吸附方法测定血清Pygo2水平,放射免疫分析法检测透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)和层粘连蛋白(LN)和全自动酶法测定血清丙氨酸氨基转移酶(ALT)和γ-谷氨酰转肽酶(γ-GT)表达量。结果 NAFL组、NASH组Pygo2表达量[52.1(12.3)、78.3(50.0)μg/L]较单纯性肥胖组[43.2(18.7)μg/L]明显升高(P0.05);NASH组Pygo2表达量较对照组[41.7(16.8)μg/L]、NAFL组明显升高(P0.001)。NAFH组HA、CⅣ、LN、ALT、γ-GT表达量较对照组、单纯性肥胖组、NAFL组明显升高(P0.001)。血清Pygo2与HA、PCⅢ、CⅣ、ALT、γ-GT、LN呈显著正相关(r=0.708、0.356、0.589、0.454、0.674,0.169,P0.05)。结论随着Pygo2表达量水平升高,肝纤维化程度加重。Pygo2与HA、CⅣ、γ-GT等指标显著相关,表明Pygo2亦可作为检测NAFLD患儿肝纤维化的临床评估指标。
[Abstract]:Objective to investigate the role of human tail limb homologue protein (Pygo2) in the progression of (NAFLD) in children with non-alcoholic fatty liver disease and to evaluate the degree of hepatic fibrosis. The purpose of this study was to detect the level of Pygo2 in the peripheral blood of obese children and to analyze the relationship between the level of Pygo2 and the traditional serum markers of hepatic fibrosis, so as to evaluate the practical clinical value of Pygo2 detection in children with NAFLD. Methods from September 2014 to February 2016, 120 hospitalized and outpatient obese children were selected from Provincial Hospital affiliated to Anhui Medical University and the first affiliated Hospital of Nanjing Medical University. According to the NAFLD guidelines, 120 obese children were divided into simple obesity group (n = 44), obese children without diffuse fatty liver by liver ultrasound (n = 44) and simple non-alcoholic fatty liver (NAFL) group (n = 35). Liver B ultrasound showed diffuse fatty liver but normal liver function, and (NASH) group (n = 41) showed diffuse fatty liver with abnormal liver function. Another 18 healthy volunteers were selected as control group. Peripheral blood samples were collected from the control group and all the patients. Serum Pygo2 levels were measured by enzyme-linked immunosorbent assay (Elisa), and (HA), 鈪，
本文编号：2323415
[Abstract]:Objective to investigate the role of human tail limb homologue protein (Pygo2) in the progression of (NAFLD) in children with non-alcoholic fatty liver disease and to evaluate the degree of hepatic fibrosis. The purpose of this study was to detect the level of Pygo2 in the peripheral blood of obese children and to analyze the relationship between the level of Pygo2 and the traditional serum markers of hepatic fibrosis, so as to evaluate the practical clinical value of Pygo2 detection in children with NAFLD. Methods from September 2014 to February 2016, 120 hospitalized and outpatient obese children were selected from Provincial Hospital affiliated to Anhui Medical University and the first affiliated Hospital of Nanjing Medical University. According to the NAFLD guidelines, 120 obese children were divided into simple obesity group (n = 44), obese children without diffuse fatty liver by liver ultrasound (n = 44) and simple non-alcoholic fatty liver (NAFL) group (n = 35). Liver B ultrasound showed diffuse fatty liver but normal liver function, and (NASH) group (n = 41) showed diffuse fatty liver with abnormal liver function. Another 18 healthy volunteers were selected as control group. Peripheral blood samples were collected from the control group and all the patients. Serum Pygo2 levels were measured by enzyme-linked immunosorbent assay (Elisa), and (HA), 鈪，
本文编号：2323415
本文链接：https://www.wllwen.com/yixuelunwen/eklw/2323415.html
最近更新
教材专著
